C4 THERAPEUTICS INC (CCCC) Fundamental Analysis & Valuation

NASDAQ:CCCC • US12529R1077

2.99 USD
-0.13 (-4.17%)
At close: Mar 11, 2026
2.93 USD
-0.06 (-2.01%)
After Hours: 3/11/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CCCC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall CCCC gets a fundamental rating of 3 out of 10. We evaluated CCCC against 519 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CCCC as it has an excellent financial health rating, but there are worries on the profitability. CCCC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. CCCC Profitability Analysis

1.1 Basic Checks

  • CCCC had negative earnings in the past year.
  • CCCC had a negative operating cash flow in the past year.
  • CCCC had negative earnings in each of the past 5 years.
  • CCCC had a negative operating cash flow in each of the past 5 years.
CCCC Yearly Net Income VS EBIT VS OCF VS FCFCCCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M

1.2 Ratios

  • CCCC has a Return On Assets of -29.24%. This is in the better half of the industry: CCCC outperforms 66.86% of its industry peers.
  • Looking at the Return On Equity, with a value of -40.92%, CCCC is in the better half of the industry, outperforming 69.36% of the companies in the same industry.
Industry RankSector Rank
ROA -29.24%
ROE -40.92%
ROIC N/A
ROA(3y)-31.52%
ROA(5y)-28.17%
ROE(3y)-47.84%
ROE(5y)-41.87%
ROIC(3y)N/A
ROIC(5y)N/A
CCCC Yearly ROA, ROE, ROICCCCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K 4K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CCCC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CCCC Yearly Profit, Operating, Gross MarginsCCCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CCCC Health Analysis

2.1 Basic Checks

  • CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CCCC has more shares outstanding than it did 1 year ago.
  • CCCC has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CCCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CCCC Yearly Shares OutstandingCCCC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CCCC Yearly Total Debt VS Total AssetsCCCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -1.21, we must say that CCCC is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of CCCC (-1.21) is comparable to the rest of the industry.
  • There is no outstanding debt for CCCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC8.79%
CCCC Yearly LT Debt VS Equity VS FCFCCCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 7.81 indicates that CCCC has no problem at all paying its short term obligations.
  • The Current ratio of CCCC (7.81) is better than 72.64% of its industry peers.
  • A Quick Ratio of 7.81 indicates that CCCC has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 7.81, CCCC is doing good in the industry, outperforming 72.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.81
Quick Ratio 7.81
CCCC Yearly Current Assets VS Current LiabilitesCCCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CCCC Growth Analysis

3.1 Past

  • CCCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.93%, which is quite good.
  • CCCC shows a small growth in Revenue. In the last year, the Revenue has grown by 1.02%.
  • Measured over the past years, CCCC shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)9.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.27%
Revenue 1Y (TTM)1.02%
Revenue growth 3Y4.95%
Revenue growth 5Y1.6%
Sales Q2Q%112.79%

3.2 Future

  • CCCC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.03% yearly.
  • The Revenue is expected to grow by 129.64% on average over the next years. This is a very strong growth
EPS Next Y7.84%
EPS Next 2Y10.45%
EPS Next 3Y8.64%
EPS Next 5Y13.03%
Revenue Next Year-27.7%
Revenue Next 2Y-14.97%
Revenue Next 3Y-2.27%
Revenue Next 5Y129.64%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CCCC Yearly Revenue VS EstimatesCCCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
CCCC Yearly EPS VS EstimatesCCCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. CCCC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CCCC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCCC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CCCC Price Earnings VS Forward Price EarningsCCCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CCCC Per share dataCCCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.45%
EPS Next 3Y8.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CCCC Dividend Analysis

5.1 Amount

  • CCCC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CCCC Fundamentals: All Metrics, Ratios and Statistics

C4 THERAPEUTICS INC

NASDAQ:CCCC (3/11/2026, 8:00:03 PM)

After market: 2.93 -0.06 (-2.01%)

2.99

-0.13 (-4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-05
Inst Owners76.74%
Inst Owner Change49.92%
Ins Owners3.74%
Ins Owner Change52.48%
Market Cap291.76M
Revenue(TTM)35.95M
Net Income(TTM)-104.99M
Analysts85.71
Price Target11.51 (284.95%)
Short Float %8.19%
Short Ratio3.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.84%
Min EPS beat(2)-6.21%
Max EPS beat(2)41.9%
EPS beat(4)3
Avg EPS beat(4)15.15%
Min EPS beat(4)-6.21%
Max EPS beat(4)41.9%
EPS beat(8)5
Avg EPS beat(8)10.85%
EPS beat(12)7
Avg EPS beat(12)9.3%
EPS beat(16)9
Avg EPS beat(16)7.85%
Revenue beat(2)2
Avg Revenue beat(2)71.25%
Min Revenue beat(2)67.19%
Max Revenue beat(2)75.3%
Revenue beat(4)3
Avg Revenue beat(4)49.67%
Min Revenue beat(4)-3.26%
Max Revenue beat(4)75.3%
Revenue beat(8)5
Avg Revenue beat(8)63.5%
Revenue beat(12)7
Avg Revenue beat(12)42.92%
Revenue beat(16)8
Avg Revenue beat(16)30.91%
PT rev (1m)14.49%
PT rev (3m)-4.82%
EPS NQ rev (1m)14%
EPS NQ rev (3m)14%
EPS NY rev (1m)8.73%
EPS NY rev (3m)13.21%
Revenue NQ rev (1m)33.79%
Revenue NQ rev (3m)33.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.12
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.37
BVpS2.63
TBVpS2.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.24%
ROE -40.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.52%
ROA(5y)-28.17%
ROE(3y)-47.84%
ROE(5y)-41.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.99%
Cap/Sales 1.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.81
Quick Ratio 7.81
Altman-Z -1.21
F-Score5
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)43.91%
Cap/Depr(5y)109.01%
Cap/Sales(3y)3.47%
Cap/Sales(5y)6.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.27%
EPS Next Y7.84%
EPS Next 2Y10.45%
EPS Next 3Y8.64%
EPS Next 5Y13.03%
Revenue 1Y (TTM)1.02%
Revenue growth 3Y4.95%
Revenue growth 5Y1.6%
Sales Q2Q%112.79%
Revenue Next Year-27.7%
Revenue Next 2Y-14.97%
Revenue Next 3Y-2.27%
Revenue Next 5Y129.64%
EBIT growth 1Y10.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.85%
EBIT Next 3Y2.43%
EBIT Next 5YN/A
FCF growth 1Y-51.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.47%
OCF growth 3YN/A
OCF growth 5YN/A

C4 THERAPEUTICS INC / CCCC FAQ

What is the fundamental rating for CCCC stock?

ChartMill assigns a fundamental rating of 3 / 10 to CCCC.


What is the valuation status of C4 THERAPEUTICS INC (CCCC) stock?

ChartMill assigns a valuation rating of 0 / 10 to C4 THERAPEUTICS INC (CCCC). This can be considered as Overvalued.


Can you provide the profitability details for C4 THERAPEUTICS INC?

C4 THERAPEUTICS INC (CCCC) has a profitability rating of 1 / 10.


How financially healthy is C4 THERAPEUTICS INC?

The financial health rating of C4 THERAPEUTICS INC (CCCC) is 7 / 10.


What is the earnings growth outlook for C4 THERAPEUTICS INC?

The Earnings per Share (EPS) of C4 THERAPEUTICS INC (CCCC) is expected to grow by 7.84% in the next year.